Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Big paydays ahead as Actavis buys Allergan for $219/share

This article was originally published in Scrip

Executive Summary

Actavis will pay $66bn in cash and stock for Allergan, which at $219 per share will generate significant returns for the Botox (onabotulinumtoxinA) maker's shareholders, including a multibillion-dollar payday for Allergan's largest shareholder Pershing Square Capital Management.

You may also be interested in...



Generic Industry Consolidation Illustrated In ANDA Holder List

Most of US FDA's approved ANDAs are owned by a handful of firms, while the vast majority of owners have between one and five.

Generic Industry Consolidation Illustrated In ANDA Holder List

Most of US FDA's approved ANDAs are owned by a handful of firms, while the vast majority of owners have between one and five.

Perrigo's Papa: Bridge Over Valeant's Troubled Waters Or Shark Bait?

Valeant Pharmaceuticals International Inc. hired Perrigo Co. PLC's Chairman and Chief Executive Joseph Papa to replace CEO Michael Pearson, but will Papa bridge the gaps between Valeant and its shareholders, debtors and the politicians who are demanding information about the company's drug pricing policies? Or, like Pearson, will he be bitten by the sharks in Valeant's troubled waters?

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

SC026948

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel